SCHEMBL4074908

SCHEMBL4074908

CCCCC(CN)(CO)CCCC

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FDPS P14324 3/20 0.41
ALDH1A1 P00352 2/20 0.35
SMPD1 P17405 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
TNNC1 P63316 5/20 0.32
SGPL1 O95470 1/20 0.32
S1PR4 O95977 1/20 0.32
S1PR1 P21453 1/20 0.32
GPR183 P32249 1/20 0.32
CERS2 Q96G23 1/20 0.32
S1PR3 Q99500 1/20 0.32
S1PR5 Q9H228 1/20 0.32
DNM1 Q05193 3/20 0.32
LMNA P02545 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
HSD17B10 Q99714 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12417217 0.95 FDPS (0.41) FDPSALDH1A1SMPD1SMN1; SMN2TNNC1
SCHEMBL10686382 0.91 FDPS (0.39) FDPSALDH1A1SMPD1SMN1; SMN2TNNC1
SCHEMBL4078244 0.84 FDPS (0.37) FDPSALDH1A1TSHR
SCHEMBL19283464 0.84 FDPS (0.39) FDPSALDH1A1SMPD1SMN1; SMN2DNM1
SCHEMBL11612056 0.84 FDPS (0.42) FDPSALDH1A1SMPD1DNM1LMNA
SCHEMBL165249 0.84 ALDH1A1 (0.42) FDPSALDH1A1SMN1; SMN2TNNC1SGPL1
SCHEMBL227493 0.84 ALDH1A1 (0.42) FDPSALDH1A1SMN1; SMN2TNNC1SGPL1
SCHEMBL2346689 0.84 ALDH1A1 (0.42) FDPSALDH1A1SMN1; SMN2TNNC1SGPL1
Ammonia Solution, Strong SCHEMBL5707582 0.81 ALDH1A1 (0.40) FDPSALDH1A1SMN1; SMN2TNNC1SGPL1
SCHEMBL5607589 0.79 DNM1 (0.39) FDPSALDH1A1SMPD1DNM1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482339-B2 2-Naphthylimino-1,3-thiazine derivative SHIONOGI AND CO., LTD. (JP) 2009-01-27 US disclosed
US-20060281738-A1 2-Naphthylimino-1,3-thiazine derivative SHIONOGI AND CO., LTD. (JP) 2006-12-14 US disclosed
EP-1659117-A1 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2006-05-24 EP disclosed
EP-0896593-A1 PROCESS FOR THE POLYMERISATION OF ALPHA-OLEFINS DSM N.V. (NL) 1999-02-17 EP disclosed
WO-1997042232-A1 PROCESS FOR THE POLYMERISATION OF ALPHA-OLEFINS DSM N.V. (NL) 1997-11-13 WO disclosed
WO-1997042233-A1 PROCESS FOR THE POLYMERIZATION OF VINYL AROMATIC MONOMERS DSM N.V. (NL) 1997-11-13 WO disclosed
WO-1997042235-A1 PROCESS FOR THE PRODUCTION OF POLYMERS CONTAINING CYCLIC OLEFINS DSM N.V. (NL) 1997-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281738-A1 2-Naphthylimino-1,3-thiazine derivative NPM1, OXTR, CYP2S1 FDPS 4622/4885ALDH1A1 1571/4885SMPD1 4308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.